Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Efficacy Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 Gene Transfer in Patients With Intermittent Claudication (WALK)
This study has been completed.
Study NCT00117650   Information provided by Genzyme

First Received on June 30, 2005.   Last Updated on October 2, 2010   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Intermittent Claudication
Peripheral Vascular Disease
Atherosclerosis
Additional conditions recognized in this trial
Peripheral Arterial Disease
Peripheral Vascular Diseases
Vascular Diseases
More general conditions related to this trial
Arterial Occlusive Diseases
Arteriosclerosis
Cardiovascular Diseases
Signs and Symptoms
Interventions listed in this trial
Ad2/HIF-1α/VP16
Saline (Placebo Control)
Additional drug interventions recognized in this trial
Etoposide
Etoposide phosphate
More general drug interventions related to this trial
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Genzyme


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services